July 2017

© 2013 Fair Isaac Corporation. Confidential.
This presentation is provided for the recipient only and cannot be reproduced or shared without Fair Isaac Corporation’s expressconsent.
CORPORATE OVERVIEW
Bradley Robinson
President and CEO
July, 2016
Salt Lake City, Utah
CONFIDENTIAL
2
Revolutionize the care of patients through novel genebased companion diagnostics and therapeutics “It is more important to know what sort of person has
a disease than to know what sort of disease a person has.”
Hippocrates, 460-370 B.C.
MISSION
3
THE GOAL:
“ELIMINATING DISEASE IN OUR GENERATION AND THE GENERATIONS
TO COME”
4
PredictiveTec hnology Group, Inc. (Bradley C. Robinson, President and CEO)
Predictive Biotech (Eric Olson,President and CEO)
Predictive Therapeutics (Mike Dey, President and CEO)
CORPORATE STRUCTURE
5
Company Highlights
Biotech
Company
Product
Portfolio
Commercial
Stage
In-House
Laboratory
• Women’s Health and Orthopedic Molecular Diagnostic Tests
• Allogenic and Autologous Stem Cell and Tissue products
• Commercial focus in Ortho, Spine, Plastics, Dermatology, Trauma.
• Focused on molecular diagnostics and companion treatments
• Proprietary and patented product candidates and technologies
• Launched first products in Q1 2016
• Extensive commercialization experience (Direct, OEM, Partner)
• In-house sales, marketing and laboratory expertise
• Objective is to have a vertically integrated CLIA and AATB accredited laboratory for rapid prototyping and development
• Control supply chain and pricing Value Proposition
• Combine patented molecular diagnostics with revolutionary companion treatment options
6
Experienced Management Team
Name Title Experience
Bradley Robinson
CEO -Predictive Technology
Group
Specialized Health Products, Infusive
Te c h n o l o g i e s , S a g e n t P h a r ma c e u ti c a l s ,
Juneau Biosciences
Mike Dey, PhD CEO -Predictive Therapeutics
Wyeth Women’s Health (President), various
management positions
Eric Olson CEO -Predictive Biotech
Skeletal Kinetics, Amedica, Axial Biotech, Medtronic
Bruce Forrest, M.D. CDO- Predictive Therapeutics Wyeth, various management positions Jack Turner VP –BusinessDevelopment Griffin Financial Group
7
Advisory Board
Name Title Experience
Ronald Barhorst
CEO -ING Financial (retired
2014)
Banking and Finance
Gregory Prince, PhD CEO –Viron Systems Developed RSV vaccine (Synagis), NIH
Nick M. Spirtos, M.D.
Medical Director –Women’s
Cancer Center of Nevada
Stanford University, Gynecologic Oncology
University Medical Advisory Board
John Sorrentino
Pfizer -COO, Pediatrics,
Vac c ines , R&D
Wyeth –Various management pos itions
Jonas Cedergen
ManagingDirector JC
Capital Advisors
Barclays Capital (London), CSFB
Ken Ward, M.D. Juneau Biosciences -CEO
29 years experience in DNA Diagnostics Board
Certified (OB/GYN, Maternal Fetal Medicine,
Medical Genetics, Molecular Genetics)
8
Predictive Technologies’ Divisions
• Endometriosis Test
• Chromic Pelvic Pain
• Infertility
• NHP07
• Proprietary therapeutic for treatment / suppression of endometriosis symptoms
• Fertility DX (Carrier Screening Test)
• Preeclampsia Test
Predictive Therapeutics Predictive Biotech
• Scoliosis Test
• Spine Deformity Test
• Degenerative Disc Disease Test
• Stem Cell and Membrane Allograft Products
• Device and Brace Companion
Tr eatment Pr oduc ts
9
STRONG INTELLECTUAL PROPERTY POSITION
10
Intellectual Property: Endometriosis
Title Ser #, Patent #
or Pub #
1
st
Named
Inventor
Status
Progestin Cannabis
Therapeutic and Method of
Use
14/281,172
US 9,149,499
US Bradley C.
Robinson
Issued
Progestin NSAID Therapeutic
and Method of Use
14/281,127
US 9,161,941
US Bradley C.
Robinson
Issued
Progestin NSAID Therapeutic
and Method of Use
PCTUS201438
6018
US Bradley C.
Robinson
National
Filing Stage
Progestin NSAID Therapeutic
and Method of Use
14/875,656
US
2016/0022696
US Bradley C.
Robinson
Pending
Method of Treating
Endometriosis
62/275,413 US Bradley C.
Robinson
Pending
Additional filings in process
11
Intellectual Property: Endometriosis
Title Ser #, Patent #
or Pub #
1
st
Named
Inventor
Status
Genetic Markers Associated with
Endometriosis and Use Thereof
12/765,643
US
2010/0272713
US Kenneth Ward Pending
Genetic Markers Associated with
Endometriosis and Use Thereof
13/159,132
US
2015/0361494
US Kenneth Ward Pending
Method of Determining
Predisposition of Endometriosis
13/603,284
US
2015/0363558
US Kenneth Ward Pending
Method of Determining
Predisposition of Endometriosis
13/788,913
US 8,932,993
US Kenneth Ward Issued
Method of Testing for
Endometriosis and Treatment
Thereof
13/789,082
US
2015/0368714
US Kenneth Ward Pending
Method of Testing for
Endometriosis and Treatment
Thereof
14/594,266
US
2015/0133382
US Kenneth Ward Pending
Additional filings in process
12
Intellectual Property: Spine
Title Ser #, Patent
# or Pub #
1
st
Named
Inventor
Status
Apparatus and Method for
Dynamic Scoliosis Orthosis
12/145,959
US 7,967,767
US Ogilvie Issued
Method of Treating Scoliosis
Using a Biological Implant and
Determining Predisposition
12/341,289
US 8,123,787
US Ogilvie Issued
Method of Treating Scoliosis
Using a Biological Implant and
Determining Predisposition
13/357,800
US 8,641,738
US Ogilvie Issued
Method of Treating Spinal
Deformity Using a Biological
Implant and Determining
Predisposition
14/170,691
US
2105/0127105
US Ogilvie Notice of
Allowance
Received
Genetic Markers Associated
with Degenerative Disc Disease
and Uses Thereof
13/364,378
US
2105/0337373
US Chettier Pending
13
Stem Cell and Tissue Products
Umbilical Cord Tissue
Allograft Liquid
Spine, Sports Medicine,
Plastics, Dermatology,
Ophthalmology
Wound and Pain Management
Amniotic Allograft
Liquid
CMF, Sports Medicine,
Plastics, Dermatology,
Pain Management
Amniotic Allograft
Membrane
Burn and Wound
Management, Plastic
Surgery, Ophthalmology ,
CMF
Autologous PRP, Adipose
and BMAC
Pain and Wound
Management, Sports
Medicine, Health and
Wellness
Near Term Opportunities
14
Stem Cell and Tissue Products
CORECYTE: Allograft Stem Cell Product
Mesenchymal Stem Cells (MSCs) derived from
Umbilical Cord Tissue. This liquid suspension product
has been assayed and contains MSCs, Hyaluronic
Acid, Proteins and Cytokines.
The allograft is minimally manipulated and can be
transplanted by physicians for several clinical
applications including: Spinal Fusion, Sports Medicine,
Plastics, Dermatology, Ophthalmology, Wound and
Pain Management treatments.
Near Term Opportunities
15
Stem Cell and Tissue Products
AMNIOCYTE Liquid: Allograft Amniotic Fluid
This liquid suspension product has been assayed and contains Hyaluronic Acid, Proteins and Cytokines derived from Amniotic Fluid.
The allograft is donated and recovered from C-section procedures. The allograft can be transplanted by physicians for several clinical applications including:
TMJ, Sports Medicine,Wound and Pain Management
treatments.
Near Term Opportunities
16
Stem Cell and Tissue Products
AMNIOCYTE Membrane: Allograft Tissue
Membrane
This allograft is donated and recovered from the
placenta. The tissue can be transplanted by
physicians for several clinical applications including:
Burn and Wound Management, Plastic Surgery,
Ophthalmology, Dental, CMF
Near Term Opportunities
17
Stem Cell and Tissue Products
AUTOCYTE: Autologous PRP, Adipose and BMAC
Stem Cells
This autologous products are harvested directly from the patient and the cells can be transplanted by physicians for several clinical applications including:
Pain and Wound Management, Sports Medicine, Health and Wellness Near Term Opportunities
18
Target Markets
Other Disease
Applications
Wound
Management
Applications
Dental
Applications
Orthopedic and
Spine Applications
Cosmetic and Plastic
Surgery Applications
Near Term Opportunities
19
Near Term Opportunities
• Endometriosis Test and Companion Therapeutic
–Proprietary genetic test for endometriosis
• Core United States patent issued January 13, 2015
–Proprietary therapeutic for the prevention and/or suppression of endometriosis
• Two United States patents issued in October 2015
• Fertility Dx Test
–Genetic test for endometriosis and extensive panel of carrier (parents’) genetic abnormalities
• Preeclampsia Test
–Genetic test providing for early identification of women at high risk for cardiovascular disease
20
Predictive Technologies: ART Guide
®
Test
Predictive Women’s Health
• >200 endometriosis markers + four questions + human fertility genes
• Actionable risk score (1-20) indicates likelihood of endometriosis
• Test will be offered at first visit with ART specialist
• First in class product with a $1.2 billion market Affymetrix Confidential
54
Commercial prototype manufactured;
first U.S. patent issued
Near Term Opportunities
21
Near Term Opportunities
• Scoliosis Test
–Proprietary genetic test predicts disease progression
–Core United States patent issued February 4, 2014
• Degenerative Disk Disease Test
–Proprietary genetic test that predicts degenerative disk disease
• Deformity of the Spine Test
–USPTO Patent Trial and Appeal Board voted unanimously in January 2016 to allow claims that add significant breadth to the spine related intellectual property
–Core United States patent issued June 21, 2016
22
Long Term Development Opportunities
• Additional Assets (DNA -600,000 samples and Genealogical Database
–HIPAA compliant
–Collected from most genetically diverse population in U.S.
–Believed to be largest DNA library in world related to women’s health
–Corresponding proprietary genealogy database developed from over 50,000 public
sources